• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 4. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Iodobenzenes

Recent Advances in the Application of 1-Cyclopropyl-4-Iodobenzene (57807-27-9) in Chemical and Pharmaceutical Research

1-Cyclopropyl-4-iodobenzene (CAS: 57807-27-9) has recently emerged as a key intermediate in the synthesis of novel pharmaceutical compounds and bioactive molecules. This aromatic iodide, characterized by its cyclopropyl substituent, has garnered significant attention due to its versatility in cross-coupling reactions and its potential applications in drug discovery. Recent studies have explored its role in the development of targeted therapies, particularly in oncology and infectious diseases, highlighting its importance in modern medicinal chemistry.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 1-cyclopropyl-4-iodobenzene in the synthesis of potent kinase inhibitors. Researchers utilized this compound as a building block in Suzuki-Miyaura cross-coupling reactions to create a series of novel compounds with enhanced selectivity for specific kinase targets. The study reported improved pharmacokinetic properties and reduced off-target effects compared to previous generations of inhibitors, suggesting promising clinical applications.

In the field of antimicrobial research, a team from the University of Cambridge recently employed 1-cyclopropyl-4-iodobenzene in the development of new quinolone derivatives. Their work, published in Antimicrobial Agents and Chemotherapy, showed that incorporation of this moiety led to compounds with improved activity against drug-resistant bacterial strains, particularly MRSA and ESBL-producing Enterobacteriaceae. The researchers attributed this enhanced activity to the unique steric and electronic properties imparted by the cyclopropyl group.

Recent advancements in synthetic methodology have also expanded the applications of 1-cyclopropyl-4-iodobenzene. A 2024 Nature Chemistry publication detailed a novel photoredox-catalyzed arylation protocol using this compound, enabling more efficient construction of complex molecular architectures under mild conditions. This breakthrough has significant implications for the synthesis of pharmaceutical compounds, particularly those containing sensitive functional groups that might not survive traditional coupling conditions.

From a safety and regulatory perspective, recent toxicological studies have confirmed the favorable profile of 1-cyclopropyl-4-iodobenzene as a synthetic intermediate. The European Chemicals Agency's 2023 assessment noted its relatively low acute toxicity and good stability under standard handling conditions, making it an attractive choice for industrial-scale pharmaceutical production. However, researchers emphasize the importance of proper handling due to its potential iodine-related reactivity.

Looking forward, the unique properties of 1-cyclopropyl-4-iodobenzene position it as a valuable tool in the development of next-generation therapeutics. Its combination of synthetic versatility and the pharmacologically beneficial cyclopropyl moiety suggests continued importance in drug discovery programs. Ongoing research is exploring its use in PROTACs (proteolysis targeting chimeras) and other targeted protein degradation platforms, potentially opening new avenues for the treatment of previously "undruggable" targets.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)